Investigating how SETD2 gene changes affect lung cancer driven by EGFR and KRAS mutations
Official title: Paradoxical Effects of SETD2 Inactivation in EGFR- and KRAS-driven Lung Adenocarcinoma
Funded at University of Pennsylvania · NIH-11088872 · Data updated 2026-11-12
This study is looking at how certain gene changes in lung cancer, especially the SETD2 gene, work together with other mutations to affect tumor growth, and it hopes to find new ways to treat patients based on their unique genetic makeup.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $37,360 |
| NIH project number | 5F31CA281076-03 |
| Project ID | NIH-11088872 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with lung adenocarcinoma who have mutations in the KRAS or EGFR genes.
✕Less likely to help
Patients without lung adenocarcinoma or those whose tumors do not have mutations in KRAS or EGFR may not benefit from this research.
What this research studies
This research explores the complex interactions between genetic mutations in lung adenocarcinoma, particularly focusing on the SETD2 gene and its effects when paired with other mutations like KRAS and EGFR. The study aims to understand how the inactivation of SETD2 can lead to different outcomes in tumor growth depending on the presence of other mutations. By examining these relationships, the research seeks to identify new therapeutic strategies that could exploit these genetic interactions to improve cancer treatment. Patients with specific genetic profiles may benefit from insights gained through this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for lung cancer that are more effective based on individual genetic profiles.
How similar studies have gone: Previous research has shown promising results in understanding genetic interactions in cancer, suggesting that this approach could yield significant insights.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Doerig, Katherine — University of Pennsylvania
- Study coordinator: Doerig, Katherine
Related research
Other NIH-funded projects on the same topics.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
-
Understanding how lung cancer and immune cells influence each other in early lung cancer development
A study looks at how lung cells and immune cells change together as early lung cancer (lung adenocarcinoma) develops, with the goal of finding points to intervene early.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Combining imaging and biopsy genes to spot aggressive vs. slow-growing early lung cancer before surgery
Aimed at people with early-stage lung adenocarcinoma, this project tests a combined imaging and biopsy gene‑marker approach to better predict tumor aggressiveness before surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.